Osiris Therapeutics, Inc. Appoints Samson Tom, PhD, MBA to Serve as President and Chief Executive Officer
November 26 2018 - 4:30PM
Osiris Therapeutics, Inc. (NASDAQ: OSIR), a regenerative medicine
company focused on developing and marketing products for wound
care, orthopedics, and sports medicine, is pleased to announce that
its Board of Directors appointed Samson Tom, PhD, MBA to serve as
President and Chief Executive Officer, effective November 26, 2018.
Dr. Tom was at Osiris from 2003 to 2011, where he held several
leadership positions spanning multiple functional areas including
Quality, Operations, Clinical Development, and Product Development.
Subsequently, he served as Group Director, Biosurgery Research
& Development at Ethicon, Inc. (a Johnson & Johnson
company). Prior to rejoining Osiris, he served as Vice President,
Research & Development for Surgical Orthobiologics at
Bioventus, LLC. Dr. Tom brings a strong combination of scientific
and commercial experience in the regenerative medicine space. He
earned a BA in Biology and Chemistry from Cornell University, a MS
and PhD in Biochemistry from the University of Rochester School of
Medicine and Dentistry, and a MBA in General Management from the
Johns Hopkins University Carey Business School.
“Returning to Osiris definitely feels like coming home,” said
Dr. Tom. “Developing and launching novel solutions to address unmet
needs for patients and the medical community have always been at
the core of Osiris. I am truly energized to continue this legacy
and look forward to working with the entire team during the next
phase in the evolution of this innovative company.”
“I am pleased to welcome Dr. Tom back to Osiris as President and
CEO,” said Peter Friedli, Chairman of the Board. “At this important
juncture for the company, Dr. Tom is a great fit due to his
familiarity with our technologies and our culture of innovation. I
look forward to working with him to achieve greater operational
efficiency and future growth.”
Jason Keefer, who previously served as Interim President and
Chief Executive Officer, will transition to lead the commercial
functions of the organization and serve on the management team as
Chief Commercial Officer.
About Osiris Therapeutics
Osiris Therapeutics, Inc., based in Columbia, Maryland,
researches, develops, manufactures and commercializes regenerative
medicine products intended to improve the health and lives of
patients and lower overall healthcare costs. We have achieved
commercial success with products in orthopedics, sports medicine
and wound care, including the Grafix product line, Stravix®, BIO4®
and Cartiform®. We continue to advance our research and
development by focusing on innovation in regenerative medicine,
including the development of bioengineered stem cell and
tissue‑based products. Osiris®, Grafix®, GrafixPL®, GrafixPL
PRIME™ Cartiform®, and Prestige Lyotechnologysm are our trademarks.
BIO4® is a trademark of Howmedica Osteonics Corp., a subsidiary of
Stryker Corporation. More information can be found on the Company’s
website, www.Osiris.com. (OSIR-G)
Forward-Looking Statements
Statements herein relating to the future of Osiris Therapeutics,
Inc. and the ongoing research and development of our products are
forward-looking statements. Osiris Therapeutics, Inc.
cautions that these forward looking statements are subject to
numerous risks and uncertainties, which could cause actual results
to differ materially from those expressed or implied by such
statements. These risks and uncertainties include those
identified under the heading “Risk Factors” in the Osiris
Therapeutics Inc. Annual Report on Form 10-K for the years ended
December 31, 2017, 2016 and 2015 and Quarterly Report on Form 10-Q
for the quarters ended March 31, 2018, June 30, 2018 and September
30, 2018 as filed with the Securities and Exchange Commission
(SEC). We caution investors not to place considerable
reliance on the forward-looking statements contained in this press
release. Examples of forward-looking statements may include,
without limitation, statements regarding the anticipated
efficiencies and advantages of products and the likelihood of
customer clinical adoption of any new products. Although well
characterized in scientific literature and studies, preservation of
tissue integrity, including cells, may not be indicative of
clinical outcome. Accordingly, you should not unduly rely on
these forward-looking statements. You are encouraged to read our
filings with the SEC, available at sec.gov, for a discussion of
these and other risks and uncertainties. The forward-looking
statements in this press release speak only as of the date of this
document, and we undertake no obligation to update or revise any of
the statements. Our business is subject to substantial risks
and uncertainties, including those referenced above. Investors,
potential investors, and others should give careful consideration
to these risks and uncertainties.
For additional information, please
contact:Diane SavoieOsiris Therapeutics, Inc.(443)
545-1834OsirisPR@Osiris.com
Osiris Therapeutics, Inc. (NASDAQ:OSIR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Osiris Therapeutics, Inc. (NASDAQ:OSIR)
Historical Stock Chart
From Apr 2023 to Apr 2024